Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2021

View Archived Issues

Shire Human Genetic Therapies describes IDS gene therapy

New influenza A virus vaccine synthesized at the University of Gdansk

Pentadefenin hydrogel developed for treating vaginitis

GS-441524 is an effective antiviral against African swine fever virus in vitro

Results of phase I trial of CRAd-S-pk7 oncolytic adenovirus delivered by neural stem cells in glioma

Possible target LGALS3BP binds to SARS-CoV-2 spike glycoprotein

Sinovent patents CDK7/cyclin H inhibitors

New protein O-GlcNAcase inhibitors discovered at Janssen Pharmaceutica

Phase Ib extension data for belapectin plus Keytruda in melanoma and head and neck cancer

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

Eli Lilly initiates phase I study of LY-3819469

Enrollment ongoing first-in-human study of PBI-200

ViiV initiates phase II study of GSK-3810109A in antiretroviral-naive HIV-1-infected adults

Ranitidine bismuth citrate shows potency for treating SARS-CoV-2 infection

Rare coding variant increases risk of Y chromosome loss, diabetes

Dosing begins in phase I study in China of IBI-323 for advanced malignant tumors

FDA clears initiation of phase II trial of pyrilutamide in androgenetic alopecia

Safety monitoring committee recommends continuation of phase IIb study of RV-001 in prostate cancer

NTLA-2001 decreases serum TTR protein concentrations through targeted knockout of TTR

Ampligen to be studied in phase IIa human challenge trial as intranasal antiviral therapy

Octenidine shows potential for treating multidrug-resistant Candida infection

Preliminary phase II data with COVID-19 vaccine candidate GRAd-COV2 support progression

Inotrem gains clearance in France and Belgium to advance nangibotide for COVID-19

Enterome begins dosing in phase I/II study of EO-2463 in indolent NHL

Amniotics to advance PulmoStem into clinic next year

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...